av Øivind Enger | mai 20, 2020 | News
US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company’s portfolio of product candidates targeting devastating rare diseases. Rallybio’s lead candidate is RLYB211 that the...
av Øivind Enger | mai 5, 2020 | News
BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020. Read...
av Øivind Enger | apr 30, 2020 | News
BerGenBio announces that bemcentinib has been selected to be fast-tracked in a new UK national multi-centre randomised Phase 2 clinicial trial initiative that aims to get an early indication of whether bemcentinib could save lives and improve outcomes in the most...
av Øivind Enger | jan 27, 2020 | News
Vaccibody AS announces that it will register on the Norwegian OTC-list (“NOTC”), owned and operated by Oslo Børs, from January 27. Vaccibody will trade under the ticker “VACC”. Read...
av Øivind Enger | nov 7, 2019 | News
Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine. The data is from the first 16 patients assessed for safety after treatment with a VB10.NEO, and the first 14 patients...
av Øivind Enger | nov 7, 2019 | News
In a communication during the Annual Meeting of the Society for Immunotherapy BerGen Bio announces that the company’s drug candidate Bemcentinib meets the primary endpoint in first cohort of Phase II NSCLC study in combination with Keytruda®. The primary efficacy...
